Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-MUC5AC Inhalation Solution in Asthma and COPD
2024-514809-67-00Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised trial of ARO-MUC5AC in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Arrowhead Pharmaceuticals. Started Jul 2024; status: completed.
02
Drugs
ARO-MUC5AC
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-514809-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514809-67-00.